Search

Your search keyword '"Gabra, Hani"' showing total 674 results
Start Over Author "Gabra, Hani"
674 results on '"Gabra, Hani"'

51. Data from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer

Author

McKie, Arthur B., primary, Vaughan, Sebastian, primary, Zanini, Elisa, primary, Okon, Imoh S., primary, Louis, Louay, primary, de Sousa, Camila, primary, Greene, Mark I., primary, Wang, Qiang, primary, Agarwal, Roshan, primary, Shaposhnikov, Dmitry, primary, Wong, Joshua L. C., primary, Gungor, Hatice, primary, Janczar, Szymon, primary, El-Bahrawy, Mona, primary, Lam, Eric W-F., primary, Chayen, Naomi E., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

52. Supplementary figure legends and the title and notes of supplementary tables from A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer

Author

Kreuzinger, Caroline, primary, Geroldinger, Angelika, primary, Smeets, Dominiek, primary, Braicu, Elena Ioana, primary, Sehouli, Jalid, primary, Koller, Julia, primary, Wolf, Andrea, primary, Darb-Esfahani, Silvia, primary, Joehrens, Korinna, primary, Vergote, Ignace, primary, Vanderstichele, Adriaan, primary, Boeckx, Bram, primary, Lambrechts, Diether, primary, Gabra, Hani, primary, Wisman, G. Bea A., primary, Trillsch, Fabian, primary, Heinze, Georg, primary, Horvat, Reinhard, primary, Polterauer, Stephan, primary, Berns, Els, primary, Theillet, Charles, primary, and Cacsire Castillo-Tong, Dan, primary

Published
2023
Full Text
View/download PDF

53. Supplementary Figure S4 from A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer

Author

Kreuzinger, Caroline, primary, Geroldinger, Angelika, primary, Smeets, Dominiek, primary, Braicu, Elena Ioana, primary, Sehouli, Jalid, primary, Koller, Julia, primary, Wolf, Andrea, primary, Darb-Esfahani, Silvia, primary, Joehrens, Korinna, primary, Vergote, Ignace, primary, Vanderstichele, Adriaan, primary, Boeckx, Bram, primary, Lambrechts, Diether, primary, Gabra, Hani, primary, Wisman, G. Bea A., primary, Trillsch, Fabian, primary, Heinze, Georg, primary, Horvat, Reinhard, primary, Polterauer, Stephan, primary, Berns, Els, primary, Theillet, Charles, primary, and Cacsire Castillo-Tong, Dan, primary

Published
2023
Full Text
View/download PDF

54. Supplementary Table 1 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer

Author

Flanagan, James M., primary, Wilson, Angela, primary, Koo, Chail, primary, Masrour, Nahal, primary, Gallon, John, primary, Loomis, Erick, primary, Flower, Kirsty, primary, Wilhelm-Benartzi, Charlotte, primary, Hergovich, Alexander, primary, Cunnea, Paula, primary, Gabra, Hani, primary, Braicu, Elena Ioana, primary, Sehouli, Jalid, primary, Darb-Esfahani, Silvia, primary, Vanderstichele, Adriaan, primary, Vergote, Ignace, primary, Kreuzinger, Caroline, primary, Castillo-Tong, Dan Cacsire, primary, Wisman, G. Bea A., primary, Berns, Els MJJ, primary, Siddiqui, Nadeem, primary, Paul, James, primary, and Brown, Robert, primary

Published
2023
Full Text
View/download PDF

55. Supplemental Table 2 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Author

Blagden, Sarah P., primary, Hamilton, Anne L., primary, Mileshkin, Linda, primary, Wong, Shirley, primary, Michael, Agnieszka, primary, Hall, Marcia, primary, Goh, Jeffrey C., primary, Lisyanskaya, Alla S., primary, DeSilvio, Michelle, primary, Frangou, Eleni, primary, Stronach, Euan A., primary, Gopalakrishna, Prashanth, primary, Meniawy, Tarek M., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

56. Supplementary Table S2 from A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer

Author

Kreuzinger, Caroline, primary, Geroldinger, Angelika, primary, Smeets, Dominiek, primary, Braicu, Elena Ioana, primary, Sehouli, Jalid, primary, Koller, Julia, primary, Wolf, Andrea, primary, Darb-Esfahani, Silvia, primary, Joehrens, Korinna, primary, Vergote, Ignace, primary, Vanderstichele, Adriaan, primary, Boeckx, Bram, primary, Lambrechts, Diether, primary, Gabra, Hani, primary, Wisman, G. Bea A., primary, Trillsch, Fabian, primary, Heinze, Georg, primary, Horvat, Reinhard, primary, Polterauer, Stephan, primary, Berns, Els, primary, Theillet, Charles, primary, and Cacsire Castillo-Tong, Dan, primary

Published
2023
Full Text
View/download PDF

57. Supplementary Table 1 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Author

Blagden, Sarah P., primary, Hamilton, Anne L., primary, Mileshkin, Linda, primary, Wong, Shirley, primary, Michael, Agnieszka, primary, Hall, Marcia, primary, Goh, Jeffrey C., primary, Lisyanskaya, Alla S., primary, DeSilvio, Michelle, primary, Frangou, Eleni, primary, Stronach, Euan A., primary, Gopalakrishna, Prashanth, primary, Meniawy, Tarek M., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

58. Supplementary Data from Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas

Author

Tan, David S.P., primary, Iravani, Marjan, primary, McCluggage, W. Glenn, primary, Lambros, Maryou B.K., primary, Milanezi, Fernanda, primary, Mackay, Alan, primary, Gourley, Charles, primary, Geyer, Felipe C., primary, Vatcheva, Radost, primary, Millar, Joanne, primary, Thomas, Karen, primary, Natrajan, Rachael, primary, Savage, Kay, primary, Fenwick, Kerry, primary, Williams, Alistair, primary, Jameson, Charles, primary, El-Bahrawy, Mona, primary, Gore, Martin E., primary, Gabra, Hani, primary, Kaye, Stanley B., primary, Ashworth, Alan, primary, and Reis-Filho, Jorge S., primary

Published
2023
Full Text
View/download PDF

59. Supplementary Data from PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas

Author

Tan, David S.P., primary, Lambros, Maryou B.K., primary, Rayter, Sydonia, primary, Natrajan, Rachael, primary, Vatcheva, Radost, primary, Gao, Qiong, primary, Marchiò, Caterina, primary, Geyer, Felipe C., primary, Savage, Kay, primary, Parry, Suzanne, primary, Fenwick, Kerry, primary, Tamber, Narinder, primary, Mackay, Alan, primary, Dexter, Tim, primary, Jameson, Charles, primary, McCluggage, W. Glenn, primary, Williams, Alistair, primary, Graham, Ashley, primary, Faratian, Dana, primary, El-Bahrawy, Mona, primary, Paige, Adam J., primary, Gabra, Hani, primary, Gore, Martin E., primary, Zvelebil, Marketa, primary, Lord, Christopher J., primary, Kaye, Stanley B., primary, Ashworth, Alan, primary, and Reis-Filho, Jorge S., primary

Published
2023
Full Text
View/download PDF

60. Supplementary Table 3 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Author

Blagden, Sarah P., primary, Hamilton, Anne L., primary, Mileshkin, Linda, primary, Wong, Shirley, primary, Michael, Agnieszka, primary, Hall, Marcia, primary, Goh, Jeffrey C., primary, Lisyanskaya, Alla S., primary, DeSilvio, Michelle, primary, Frangou, Eleni, primary, Stronach, Euan A., primary, Gopalakrishna, Prashanth, primary, Meniawy, Tarek M., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

61. Supplementary Table 4 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer

Author

Flanagan, James M., primary, Wilson, Angela, primary, Koo, Chail, primary, Masrour, Nahal, primary, Gallon, John, primary, Loomis, Erick, primary, Flower, Kirsty, primary, Wilhelm-Benartzi, Charlotte, primary, Hergovich, Alexander, primary, Cunnea, Paula, primary, Gabra, Hani, primary, Braicu, Elena Ioana, primary, Sehouli, Jalid, primary, Darb-Esfahani, Silvia, primary, Vanderstichele, Adriaan, primary, Vergote, Ignace, primary, Kreuzinger, Caroline, primary, Castillo-Tong, Dan Cacsire, primary, Wisman, G. Bea A., primary, Berns, Els MJJ, primary, Siddiqui, Nadeem, primary, Paul, James, primary, and Brown, Robert, primary

Published
2023
Full Text
View/download PDF

63. Supplementary Table 2 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer

Author

Flanagan, James M., primary, Wilson, Angela, primary, Koo, Chail, primary, Masrour, Nahal, primary, Gallon, John, primary, Loomis, Erick, primary, Flower, Kirsty, primary, Wilhelm-Benartzi, Charlotte, primary, Hergovich, Alexander, primary, Cunnea, Paula, primary, Gabra, Hani, primary, Braicu, Elena Ioana, primary, Sehouli, Jalid, primary, Darb-Esfahani, Silvia, primary, Vanderstichele, Adriaan, primary, Vergote, Ignace, primary, Kreuzinger, Caroline, primary, Castillo-Tong, Dan Cacsire, primary, Wisman, G. Bea A., primary, Berns, Els MJJ, primary, Siddiqui, Nadeem, primary, Paul, James, primary, and Brown, Robert, primary

Published
2023
Full Text
View/download PDF

64. Supplementary Figure 5 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3

Author

Gourley, Charlie, primary, Paige, Adam J.W., primary, Taylor, Karen J., primary, Ward, Carol, primary, Kuske, Barbara, primary, Zhang, Jieqing, primary, Sun, Mingjun, primary, Janczar, Szymon, primary, Harrison, David J., primary, Muir, Morwenna, primary, Smyth, John F., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

65. Supplementary Methods, Legends for Figures 1-5 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3

Author

Gourley, Charlie, primary, Paige, Adam J.W., primary, Taylor, Karen J., primary, Ward, Carol, primary, Kuske, Barbara, primary, Zhang, Jieqing, primary, Sun, Mingjun, primary, Janczar, Szymon, primary, Harrison, David J., primary, Muir, Morwenna, primary, Smyth, John F., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

66. Data from HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer

Author

Stronach, Euan A., primary, Alfraidi, Albandri, primary, Rama, Nona, primary, Datler, Christoph, primary, Studd, James B., primary, Agarwal, Roshan, primary, Guney, Tankut G., primary, Gourley, Charlie, primary, Hennessy, Bryan T., primary, Mills, Gordon B., primary, Mai, Antonello, primary, Brown, Robert, primary, Dina, Roberto, primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

67. Supplementary Figure 3 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3

Author

Gourley, Charlie, primary, Paige, Adam J.W., primary, Taylor, Karen J., primary, Ward, Carol, primary, Kuske, Barbara, primary, Zhang, Jieqing, primary, Sun, Mingjun, primary, Janczar, Szymon, primary, Harrison, David J., primary, Muir, Morwenna, primary, Smyth, John F., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

68. Supplementary Table 1A from HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer

Author

Stronach, Euan A., primary, Alfraidi, Albandri, primary, Rama, Nona, primary, Datler, Christoph, primary, Studd, James B., primary, Agarwal, Roshan, primary, Guney, Tankut G., primary, Gourley, Charlie, primary, Hennessy, Bryan T., primary, Mills, Gordon B., primary, Mai, Antonello, primary, Brown, Robert, primary, Dina, Roberto, primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

69. Supplementary Figure 4 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3

Author

Gourley, Charlie, primary, Paige, Adam J.W., primary, Taylor, Karen J., primary, Ward, Carol, primary, Kuske, Barbara, primary, Zhang, Jieqing, primary, Sun, Mingjun, primary, Janczar, Szymon, primary, Harrison, David J., primary, Muir, Morwenna, primary, Smyth, John F., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

70. Supplementary Figure 2 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3

Author

Gourley, Charlie, primary, Paige, Adam J.W., primary, Taylor, Karen J., primary, Ward, Carol, primary, Kuske, Barbara, primary, Zhang, Jieqing, primary, Sun, Mingjun, primary, Janczar, Szymon, primary, Harrison, David J., primary, Muir, Morwenna, primary, Smyth, John F., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

71. Supplementary Table 4 from HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer

Author

Stronach, Euan A., primary, Alfraidi, Albandri, primary, Rama, Nona, primary, Datler, Christoph, primary, Studd, James B., primary, Agarwal, Roshan, primary, Guney, Tankut G., primary, Gourley, Charlie, primary, Hennessy, Bryan T., primary, Mills, Gordon B., primary, Mai, Antonello, primary, Brown, Robert, primary, Dina, Roberto, primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

72. Supplementary Methods, Tables, 2, 3, and 5, Figures 1-10 from HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer

Author

Stronach, Euan A., primary, Alfraidi, Albandri, primary, Rama, Nona, primary, Datler, Christoph, primary, Studd, James B., primary, Agarwal, Roshan, primary, Guney, Tankut G., primary, Gourley, Charlie, primary, Hennessy, Bryan T., primary, Mills, Gordon B., primary, Mai, Antonello, primary, Brown, Robert, primary, Dina, Roberto, primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

74. Supplementary Figure 1 from WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin α3

Author

Gourley, Charlie, primary, Paige, Adam J.W., primary, Taylor, Karen J., primary, Ward, Carol, primary, Kuske, Barbara, primary, Zhang, Jieqing, primary, Sun, Mingjun, primary, Janczar, Szymon, primary, Harrison, David J., primary, Muir, Morwenna, primary, Smyth, John F., primary, and Gabra, Hani, primary

Published
2023
Full Text
View/download PDF

76. Molecular and cell genetic analysis of chromosome 11 in sporadic epithelial ovarian cancer

Author

Gabra, Hani

Subjects
616.994
Abstract

I used PCR based polymorphic microsatellites to define frequent loss of heterozygosity (LOH) at 11p15.5-15.1 and 11q23-qter in DNA blood/tumour pairs from 60 patients with ovarian neoplasms. LOH at 11q23-qter was significantly associated with advantaged stage and adverse actuarial survival. Integration of this LOH data allowed construction of a multistep model for ovarian cancer. Refinement of the 11q23-qter region revealed an 8.5Mb LOH region between D11S934 and D11S1320 (11q23.3-q24.3) retaining the above survival association. To test the causality of the LOH observations, I introduced normal chr 11 by microcell mediated chromosome transfer (MMCT) into an ovarian cancer cell line. I used 556.1.5, a human monochromosome somatic cell hybrid to transfer neor-tagged chr 11 into Hygr subline of OVCAR3 (OH3), an ovarian cancer line with a chr 11 rearrangement. I have analysed 14 microcell hybrid clones (MHCs) from 5 experiments. Chr 11 transfer was confirmed by PCR, in situ hybridisation and microsatellite analysis. Interestingly, chr 12 MMCT, originally intended as a negative control was shown to inhibit the growth of OH3, suggesting the presence of a TSG on this chromosome. Chr11 MHCs remained immortalised, and demonstrated significant in vitro growth inhibition. This inhibition was not due to cell cycle block (DNA FACS analysis) or apoptosis (FITC-labelled Annexin-V and fluoro-TUNEL FACS analysis). MHCs were significantly reduced in their ability to invade matrigel in the transwell invasion assay. MHCs retaining whole chr 11 showed significant reduction in invasiveness compared with MHCs taking up all chr 11 as far as 11q22. Soft agar clonogenicity was unaltered. Xenographs of chr 11 MHCs showed growth delay rather than suppression of tumorigenicity. These studies suggest that the gene(s) on chromosome 11 functions as an ovarian cancer progression-suppressor and provides a starting point for an integrated positional/functional cloning approach.

Published
1997

82. ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Glajzer, Jacek, primary, Castillo-Tong, Dan Cacsire, additional, Richter, Rolf, additional, Vergote, Ignace, additional, Kulbe, Hagen, additional, Vanderstichele, Adriaan, additional, Ruscito, Ilary, additional, Trillsch, Fabian, additional, Mustea, Alexander, additional, Kreuzinger, Caroline, additional, Gourley, Charlie, additional, Gabra, Hani, additional, Taube, Eliane T., additional, Dorigo, Oliver, additional, Horst, David, additional, Keunecke, Carlotta, additional, Baum, Joanna, additional, Angelotti, Timothy, additional, Sehouli, Jalid, additional, and Braicu, Elena Ioana, additional

Published
2022
Full Text
View/download PDF

83. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium

Author

Glajzer, Jacek, primary, Castillo-Tong, Dan Cacsire, additional, Richter, Rolf, additional, Vergote, Ignace, additional, Kulbe, Hagen, additional, Vanderstichele, Adriaan, additional, Ruscito, Ilary, additional, Trillsch, Fabian, additional, Mustea, Alexander, additional, Kreuzinger, Caroline, additional, Gourley, Charlie, additional, Gabra, Hani, additional, Taube, Eliane T., additional, Dorigo, Oliver, additional, Horst, David, additional, Keunecke, Carlotta, additional, Baum, Joanna, additional, Angelotti, Timothy, additional, Sehouli, Jalid, additional, and Braicu, Elena Ioana, additional

Published
2022
Full Text
View/download PDF

85. Impact of lympho‐vascular space invasion on tumor characteristics and survival outcome of women with low‐grade serous ovarian carcinoma

Author

Matsuo, Koji, Wong, Kwong‐Kwok, Fotopoulou, Christina, Blake, Erin A., Robertson, Sharon E., Pejovic, Tanja, Frimer, Marina, Pardeshi, Vishakha, Hu, Wei, Choi, Jong‐Sun, Sun, Charlotte C., Richmond, Abby M., Marcus, Jenna Z., Hilliard, Maren A.M., Mostofizadeh, Sayedamin, Mhawech‐Fauceglia, Paulette, Abdulfatah, Eman, Post, Miriam D., Saglam, Ozlen, Shahzad, Mian M.K., Karabakhtsian, Rouzan G., Ali‐Fehmi, Rouba, Gabra, Hani, Roman, Lynda D., Sood, Anil K., and Gershenson, David M.

Published
2018
Full Text
View/download PDF

92. Whole–genome characterization of chemoresistant ovarian cancer

Author

Patch, Ann-Marie, Christie, Elizabeth L., Etemadmoghadam, Dariush, Garsed, Dale W., George, Joshy, Fereday, Sian, Nones, Katia, Cowin, Prue, Alsop, Kathryn, Bailey, Peter J., Kassahn, Karin S., Newell, Felicity, Quinn, Michael C. J., Kazakoff, Stephen, Quek, Kelly, Wilhelm-Benartzi, Charlotte, Curry, Ed, Leong, Huei San, Hamilton, Anne, Mileshkin, Linda, Au-Yeung, George, Kennedy, Catherine, Hung, Jillian, Chiew, Yoke-Eng, Harnett, Paul, Friedlander, Michael, Quinn, Michael, Pyman, Jan, Cordner, Stephen, O’Brien, Patricia, Leditschke, Jodie, Young, Greg, Strachan, Kate, Waring, Paul, Azar, Walid, Mitchell, Chris, Traficante, Nadia, Hendley, Joy, Thorne, Heather, Shackleton, Mark, Miller, David K., Arnau, Gisela Mir, Tothill, Richard W., Holloway, Timothy P., Semple, Timothy, Harliwong, Ivon, Nourse, Craig, Nourbakhsh, Ehsan, Manning, Suzanne, Idrisoglu, Senel, Bruxner, Timothy J. C., Christ, Angelika N., Poudel, Barsha, Holmes, Oliver, Anderson, Matthew, Leonard, Conrad, Lonie, Andrew, Hall, Nathan, Wood, Scott, Taylor, Darrin F., Xu, Qinying, Fink, J. Lynn, Waddell, Nick, Drapkin, Ronny, Stronach, Euan, Gabra, Hani, Brown, Robert, Jewell, Andrea, Nagaraj, Shivashankar H., Markham, Emma, Wilson, Peter J., Ellul, Jason, McNally, Orla, Doyle, Maria A., Vedururu, Ravikiran, Stewart, Collin, Lengyel, Ernst, Pearson, John V., Waddell, Nicola, deFazio, Anna, Grimmond, Sean M., and Bowtell, David D. L.

Published
2015
Full Text
View/download PDF

94. Trametinib versus standard of care in patients with recurrent\ud low-grade serous ovarian cancer (GOG 281/LOGS):\ud an international, randomised, open-label, multicentre,\ud phase 2/3 trial

Author

Gershenson, David M., Miller, Austin, Brady, William E., Paul, James, Carty, Karen, Rodgers, William, Millan, David, Coleman, Robert L., Moore, Kathleen N., Banerjee, Susana, Connolly, Kate, Secord, Angeles Alvarez, O'Malley, David M., Dorigo, Oliver, Gaillard, Stephanie, Gabra, Hani, Slomovitz, Brian, Hanjani, Parviz, Farley, John, Churchman, Michael, Ewing, Ailith, Hollis, Robert L., Herrington, C. Simon, Huang, Helen Q., Wenzel, Lari, and Gourley, Charlie

Abstract

Background:\ud Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with recurrent low-grade serous carcinoma.\ud Methods:\ud This international, randomised, open-label, multicentre, phase 2/3 trial was done at 84 hospitals in the USA and UK. Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen, but not all five standard-of-care drugs, and had received an unlimited number of previous regimens. Patients with serous borderline tumours or tumours containing low-grade serous and high-grade serous carcinoma were excluded. Eligible patients were randomly assigned (1:1) to receive either oral trametinib 2 mg once daily (trametinib group) or one of five standard-of-care treatment options (standard-of-care group): intravenous paclitaxel 80 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40–50 mg/m2 by body surface area once every 4 weeks; intravenous topotecan 4 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. Randomisation was stratified by geographical region (USA or UK), number of previous regimens (1, 2, or ≥3), performance status (0 or 1), and planned standard-of-care regimen. The primary endpoint was investigator-assessed progression-free survival while receiving randomised therapy, as assessed by imaging at baseline, once every 8 weeks for 15 months, and then once every 3 months thereafter, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02101788, and is active but not recruiting.\ud Findings:\ud Between Feb 27, 2014, and April 10, 2018, 260 patients were enrolled and randomly assigned to the trametinib group (n=130) or the standard-of-care group (n=130). At the primary analysis, there were 217 progression-free survival events (101 [78%] in the trametinib group and 116 [89%] in the standard-of-care group). Median progression-free survival in the trametinib group was 13·0 months (95% CI 9·9–15·0) compared with 7·2 months (5·6–9·9) in the standard-of-care group (hazard ratio 0·48 [95% CI 0·36–0·64]; p

Published
2022

95. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomised, open-label phase 2/3 trial

Author

M. Gershenson, David, Miller, Austin, E Brady, William, Paul, James, Carty, Karen, Rodgers, William, Millan, David, L Coleman, Robert, N Moore, Kathleen, Banerjee, Susana, Connolly, Kate, Alvarez Secord, Angeles, M O'Malley, David, Dorigo, Oliver, Gaillard, Stephanie, Gabra, Hani, Slomovitz, Brian, Hanjani, Parviz, Farley, John, Churchman, Michael, Ewing, Ailith, Hollis, Robb, Herrington, C Simon, Q Huang, Helen, B Wenzel, Lari, and Gourley, Charlie

Subjects
Adult, Pyridones/administration & dosage, Administration, Oral, Ovarian Neoplasms/drug therapy, Standard of Care, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Progression-Free Survival, United Kingdom, United States, Treatment Outcome, Paclitaxel/administration & dosage, Humans, Female, MAP Kinase Kinase 1/metabolism, Pyrimidinones/administration & dosage, Neoplasm Grading, Neoplasm Recurrence, Local/pathology, Aged, Carcinoma, Ovarian Epithelial/drug therapy
Abstract

BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with recurrent low-grade serous carcinoma.METHODS: This international, randomised, open-label, multicentre, phase 2/3 trial was done at 84 hospitals in the USA and UK. Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen, but not all five standard-of-care drugs, and had received an unlimited number of previous regimens. Patients with serous borderline tumours or tumours containing low-grade serous and high-grade serous carcinoma were excluded. Eligible patients were randomly assigned (1:1) to receive either oral trametinib 2 mg once daily (trametinib group) or one of five standard-of-care treatment options (standard-of-care group): intravenous paclitaxel 80 mg/m 2 by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40-50 mg/m 2 by body surface area once every 4 weeks; intravenous topotecan 4 mg/m 2 by body surface area on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. Randomisation was stratified by geographical region (USA or UK), number of previous regimens (1, 2, or ≥3), performance status (0 or 1), and planned standard-of-care regimen. The primary endpoint was investigator-assessed progression-free survival while receiving randomised therapy, as assessed by imaging at baseline, once every 8 weeks for 15 months, and then once every 3 months thereafter, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02101788, and is active but not recruiting. FINDINGS: Between Feb 27, 2014, and April 10, 2018, 260 patients were enrolled and randomly assigned to the trametinib group (n=130) or the standard-of-care group (n=130). At the primary analysis, there were 217 progression-free survival events (101 [78%] in the trametinib group and 116 [89%] in the standard-of-care group). Median progression-free survival in the trametinib group was 13·0 months (95% CI 9·9-15·0) compared with 7·2 months (5·6-9·9) in the standard-of-care group (hazard ratio 0·48 [95% CI 0·36-0·64]; pINTERPRETATION: Trametinib represents a new standard-of-care option for patients with recurrent low-grade serous carcinoma.FUNDING: NRG Oncology, Cancer Research UK, Target Ovarian Cancer, and Novartis.

Published
2022
Full Text
View/download PDF

97. P-OGC39 The smell of oesophageal adenocarcinoma: opportunities for tests and treatments

Author

Antonowicz, Stefan, primary, Abbassi-Ghadi, Nima, additional, Bodai, Zsolt, additional, Wiggins, Tom, additional, Markar, Sheraz, additional, Boshier, Piers, additional, Goh, Yan Mei, additional, Adam, Mina, additional, Lu, Haonan, additional, Kudo, Hiromi, additional, Rosini, Francesca, additional, Goldin, Robert, additional, Moralli, Daniella, additional, Green, Catherine, additional, Peters, Chris, additional, Habib, Nagy, additional, Gabra, Hani, additional, Fitzgerald, Rebecca, additional, Takats, Zoltan, additional, and Hanna, George, additional

Published
2021
Full Text
View/download PDF

98. Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Author

Loges, Sonja, primary, Sutamtewagul, Grerk, additional, Heuser, Michael, additional, Chromik, Jörg, additional, Kapp-Schwoerer, Silke, additional, Crugnola, Monica, additional, Di Renzo, Nicola, additional, Lemoli, Roberto M., additional, Mattei, Daniele Giovanni, additional, Ben Batalla, Isabel, additional, Hellesøy, Monica, additional, Waizenegger, Jonas, additional, Janning, Melanie, additional, Imbusch, Charles D., additional, Beumer, Niklas, additional, Rayford, Austin, additional, Nautiyal, Jaya, additional, Berkman-Gottlieb, Tzivia, additional, Micklem, David, additional, Gabra, Hani, additional, Gorcea-Carson, Claudia, additional, Lorens, James B., additional, Fiedler, Walter, additional, Alvarado, Yesid, additional, Gjertsen, Bjorn T., additional, and Rieckmann, Lisa-Marie, additional

Published
2021
Full Text
View/download PDF

99. 602 AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells

Author

Li, Huiyu, primary, Liu, Zhida, additional, Liu, Longchao, additional, Zhang, Hongyi, additional, Han, Chuanhui, additional, Girard, Luc, additional, Park, Hyunsil, additional, Zhang, Anli, additional, Dong, Chunbo, additional, Ye, Jianfeng, additional, Rayford, Austin, additional, Peyton, Michael, additional, Li, Xiaoguang, additional, Avila, Kim, additional, Cao, Xuezhi, additional, Hu, Shuiqing, additional, Akbay, Esra, additional, Solis, Luisa, additional, Behrens, Carmen, additional, Hernandez-Ruiz, Sharia, additional, Wei, Lu, additional, Wistuba, Ignacio, additional, Heymach, John, additional, Chisamore, Michael, additional, Micklem, David, additional, Gabra, Hani, additional, Gausdal, Gro, additional, Lorens, James, additional, Li, Bo, additional, Fu, Yang-Xin, additional, Minna, John, additional, and Brekken, Rolf, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results